TWI609686B - 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 - Google Patents
使用馬賽替尼治療以預測因子所識別的癌症患者亞群 Download PDFInfo
- Publication number
- TWI609686B TWI609686B TW102136110A TW102136110A TWI609686B TW I609686 B TWI609686 B TW I609686B TW 102136110 A TW102136110 A TW 102136110A TW 102136110 A TW102136110 A TW 102136110A TW I609686 B TWI609686 B TW I609686B
- Authority
- TW
- Taiwan
- Prior art keywords
- pain
- treatment
- patient
- patients
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ??12306214.3 | 2012-10-04 | ||
| EP12306214 | 2012-10-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201414475A TW201414475A (zh) | 2014-04-16 |
| TWI609686B true TWI609686B (zh) | 2018-01-01 |
Family
ID=47073382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102136110A TWI609686B (zh) | 2012-10-04 | 2013-10-04 | 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10238649B2 (OSRAM) |
| EP (1) | EP2903616B8 (OSRAM) |
| JP (1) | JP6234466B2 (OSRAM) |
| KR (1) | KR102149483B1 (OSRAM) |
| CN (1) | CN104968347A (OSRAM) |
| AR (1) | AR092899A1 (OSRAM) |
| AU (1) | AU2013326463B2 (OSRAM) |
| BR (1) | BR112015007144A2 (OSRAM) |
| CA (1) | CA2886979C (OSRAM) |
| DK (1) | DK2903616T3 (OSRAM) |
| EA (1) | EA037368B1 (OSRAM) |
| ES (1) | ES2656640T3 (OSRAM) |
| IL (1) | IL238107B (OSRAM) |
| MX (1) | MX369999B (OSRAM) |
| NZ (1) | NZ706420A (OSRAM) |
| SG (1) | SG11201502626PA (OSRAM) |
| SI (1) | SI2903616T1 (OSRAM) |
| TW (1) | TWI609686B (OSRAM) |
| WO (1) | WO2014053650A1 (OSRAM) |
| ZA (1) | ZA201503054B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201514311A (zh) * | 2013-10-04 | 2015-04-16 | Ab Science | 用於判定胰臟癌預後之方法 |
| RU2016147946A (ru) * | 2014-05-08 | 2018-06-08 | Онкоэтикс Гмбх | Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений |
| TW201615223A (zh) * | 2014-10-24 | 2016-05-01 | 朗齊生物醫學股份有限公司 | 驅蟲藥臨床新應用 |
| EP3280448B1 (en) | 2015-04-10 | 2020-12-30 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| SMT202100416T1 (it) | 2016-03-02 | 2021-09-14 | Eisai R&D Man Co Ltd | Coniugati anticorpo-farmaco a base di eribulina e metodi di uso |
| AU2017236177B2 (en) * | 2016-03-25 | 2022-03-31 | Ab Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
| CN107267454B (zh) * | 2016-04-07 | 2025-05-23 | 内蒙古原生元生物科技有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| US11400086B2 (en) * | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
| KR102708050B1 (ko) * | 2018-01-31 | 2024-09-24 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
| US20210398672A1 (en) * | 2018-10-29 | 2021-12-23 | Northwestern University | Big Data-Driven Personalized Management of Chronic Pain |
| WO2020115108A1 (en) * | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2020115261A1 (en) * | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| CA3150433A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| CN111759857A (zh) * | 2020-06-30 | 2020-10-13 | 宁波市微循环与莨菪类药研究所 | Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201130830A (en) * | 2010-02-01 | 2011-09-16 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| CA2494695C (en) | 2002-08-02 | 2011-04-05 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| WO2007015935A2 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
| US20100143935A1 (en) * | 2006-12-01 | 2010-06-10 | Apocell, Inc. | c-KIT Phosphorylation in Cancer |
| WO2008084103A1 (en) | 2007-01-12 | 2008-07-17 | Ab Science | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors |
| CN101657446B (zh) | 2007-02-13 | 2013-05-15 | Ab科学有限公司 | 合成作为激酶抑制剂的2-氨基噻唑化合物的方法 |
| US20120264639A1 (en) | 2009-11-04 | 2012-10-18 | Jen Jen Yeh | Methods and compositions for predicting survival in subjects with cancer |
| WO2012170640A1 (en) * | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
-
2013
- 2013-10-04 BR BR112015007144A patent/BR112015007144A2/pt not_active Application Discontinuation
- 2013-10-04 DK DK13773731.8T patent/DK2903616T3/da active
- 2013-10-04 EA EA201500373A patent/EA037368B1/ru unknown
- 2013-10-04 JP JP2015535036A patent/JP6234466B2/ja active Active
- 2013-10-04 AU AU2013326463A patent/AU2013326463B2/en not_active Ceased
- 2013-10-04 TW TW102136110A patent/TWI609686B/zh not_active IP Right Cessation
- 2013-10-04 CN CN201380063241.4A patent/CN104968347A/zh active Pending
- 2013-10-04 CA CA2886979A patent/CA2886979C/en active Active
- 2013-10-04 US US14/433,198 patent/US10238649B2/en active Active
- 2013-10-04 SG SG11201502626PA patent/SG11201502626PA/en unknown
- 2013-10-04 ES ES13773731.8T patent/ES2656640T3/es active Active
- 2013-10-04 KR KR1020157011764A patent/KR102149483B1/ko active Active
- 2013-10-04 WO PCT/EP2013/070741 patent/WO2014053650A1/en not_active Ceased
- 2013-10-04 EP EP13773731.8A patent/EP2903616B8/en active Active
- 2013-10-04 SI SI201330891T patent/SI2903616T1/en unknown
- 2013-10-04 AR ARP130103596A patent/AR092899A1/es unknown
- 2013-10-04 NZ NZ706420A patent/NZ706420A/en not_active IP Right Cessation
- 2013-10-04 MX MX2015004264A patent/MX369999B/es active IP Right Grant
-
2015
- 2015-04-01 IL IL238107A patent/IL238107B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/03054A patent/ZA201503054B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201130830A (en) * | 2010-02-01 | 2011-09-16 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015007144A2 (pt) | 2017-12-12 |
| SI2903616T1 (en) | 2018-02-28 |
| CA2886979A1 (en) | 2014-04-10 |
| EP2903616B1 (en) | 2017-12-13 |
| JP2015532296A (ja) | 2015-11-09 |
| AU2013326463B2 (en) | 2018-01-18 |
| ES2656640T3 (es) | 2018-02-27 |
| US10238649B2 (en) | 2019-03-26 |
| SG11201502626PA (en) | 2015-05-28 |
| MX2015004264A (es) | 2015-10-12 |
| KR20150092739A (ko) | 2015-08-13 |
| EP2903616A1 (en) | 2015-08-12 |
| AR092899A1 (es) | 2015-05-06 |
| DK2903616T3 (da) | 2018-01-29 |
| EA201500373A1 (ru) | 2016-02-29 |
| EA037368B1 (ru) | 2021-03-19 |
| CN104968347A (zh) | 2015-10-07 |
| JP6234466B2 (ja) | 2017-11-22 |
| US20150272945A1 (en) | 2015-10-01 |
| MX369999B (es) | 2019-11-28 |
| IL238107B (en) | 2018-03-29 |
| TW201414475A (zh) | 2014-04-16 |
| NZ706420A (en) | 2018-08-31 |
| AU2013326463A1 (en) | 2015-04-16 |
| KR102149483B1 (ko) | 2020-08-28 |
| CA2886979C (en) | 2021-01-05 |
| ZA201503054B (en) | 2016-11-30 |
| WO2014053650A1 (en) | 2014-04-10 |
| EP2903616B8 (en) | 2018-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI609686B (zh) | 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 | |
| Schuler et al. | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial | |
| JP2025179063A (ja) | 素行障害の診断及び治療方法 | |
| Hata et al. | Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection | |
| CA2850175C (en) | Biomarkers for predicting sensitivity to cancer treatments | |
| KR20150131312A (ko) | 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료 | |
| US11136625B2 (en) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same | |
| Thomas et al. | PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant | |
| Harrison et al. | Treatment of Glioblastoma in the Elderly | |
| Yan et al. | Molecular biomarker‐guided anti‐angiogenic targeted therapy for malignant glioma | |
| US20180263979A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| JP2017511341A (ja) | Ｎｒａｓ変異癌の処置における使用のためのｅｇｆｒ阻害剤とｍｅｋ阻害剤の組合せ | |
| US20200071765A1 (en) | Cancer treatments and methods of selecting same | |
| US9808469B2 (en) | Antitumor activity of multi-kinase inhibitors in triple negative breast cancer | |
| Li et al. | [Retracted] The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta‐Analysis | |
| Bolzacchini et al. | Safety report of TAS-102 in a patient with reduced DPD activity | |
| US20200316067A1 (en) | Combination of raf inhibitors and taxanes | |
| Yi et al. | Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors | |
| Nazarov et al. | Effects of n-Myc and c-Myc on the expression of p53 family members and their transcriptional targets in human neuroblastoma cells | |
| JP2025507955A (ja) | 癌の治療のための精密療法 | |
| Wang et al. | Therapeutic effect of gefitinib in advanced non-small cell lung cancer and its effect on the EGFR level in peripheral blood | |
| Hill | Biological mechanisms of disease relapse in childhood medulloblastoma | |
| Mateos | Evaluation of risk of acute lymphoblastic leukaemia treatment-related side-effects: the ERASE study | |
| Journe et al. | 254 cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines | |
| Haegebarth et al. | Synergistic Activity of IDH1 Inhibitor BAY1436032 with Azacitidine in |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |